PICALM rs3851050: Understanding Your Alzheimer's Risk Marker
The genetic variant rs3851050 is a common single-nucleotide polymorphism located near the PICALM gene on chromosome 11. Large-scale genome-wide association studies have identified this locus as a contributor to late-onset Alzheimer's disease susceptibility, with alleles modestly altering statistical risk. However, it is an indirect susceptibility marker with small individual effect sizes rather than a deterministic clinical diagnosis.
What each genotype means
Typical PICALM variant profile
This genotype represents one of the common configurations for the rs3851050 variant near the PICALM gene. Research indicates that variants in this region are associated with altered susceptibility to late-onset Alzheimer's disease, though the individual impact of this specific genotype remains limited and requires further study. This information is for educational purposes and does not constitute a medical diagnosis or risk assessment.
This genotype is common, reflecting the high minor allele frequency of approximately 0.35-0.45 observed for this variant across European and Asian populations.
Typical PICALM variant profile
This genotype represents one of the common configurations for the rs3851050 variant near the PICALM gene. Research indicates that variants in this region are associated with altered susceptibility to late-onset Alzheimer's disease, though the individual impact of this specific genotype remains limited and requires further study. This information is for educational purposes and does not constitute a medical diagnosis or risk assessment.
This genotype is common, reflecting the high minor allele frequency of approximately 0.35-0.45 observed for this variant across European and Asian populations.
Typical PICALM variant profile
This genotype represents one of the common configurations for the rs3851050 variant near the PICALM gene. Research indicates that variants in this region are associated with altered susceptibility to late-onset Alzheimer's disease, though the individual impact of this specific genotype remains limited and requires further study. This information is for educational purposes and does not constitute a medical diagnosis or risk assessment.
This genotype is common, reflecting the high minor allele frequency of approximately 0.35-0.45 observed for this variant across European and Asian populations.
Genetic Architecture and Genomic Location
The single-nucleotide polymorphism rs3851050 represents a common genomic variation positioned adjacent to the PICALM (phosphatidylinositol binding clathrin assembly protein) gene locus on the long arm of human chromosome 11 (11q14). In genetic catalogs such as dbSNP, rs3851050 is documented primarily as an intergenic or regulatory non-coding transition involving guanine (G) and adenine (A) alleles (often reported in reverse complement orientation as C and T in various array platforms). Because it resides outside the protein-coding exons of the gene, the variant does not alter the underlying amino acid sequence of the resulting protein. Instead, genomic research suggests that rs3851050 acts as a proxy or regulatory marker in strong linkage disequilibrium with functional elements that influence transcriptional activity and chromatin accessibility in brain tissues.
Biological Role of the PICALM Gene
The PICALM gene encodes a vital clathrin-adaptor protein heavily involved in clathrin-mediated endocytosis, intracellular vesicle trafficking, and macroautophagy. Within the central nervous system, PICALM is expressed across multiple cell types, including neurons, microglial immune cells, and brain endothelial cells forming the blood-brain barrier. Cell-biology investigations indicate that PICALM plays a critical role in clearing neurotoxic amyloid-beta proteins by facilitating their internalization, lysosomal transport, and transcytosis out of brain tissue. Recent functional studies also reveal that genetic modulation of PICALM expression in microglia impacts endocytic clearance and aberrant lipid droplet accumulation. Perturbations in PICALM-mediated vesicle processing can therefore alter basic neuroimmune maintenance, promoting neuropathological cascades associated with neurodegeneration.
Evidence Strength and Disease Association
Multiple large-scale genome-wide association studies (GWAS) and systematic meta-analyses curated in the GWAS Catalog have repeatedly flagged the PICALM region as one of the most reproducible non-APOE susceptibility loci for late-onset Alzheimer's disease (LOAD). The minor allele (frequently cited as the G allele on the genomic forward strand, corresponding to A on the opposite strand) has been associated with modest protection or reduced relative odds of developing Alzheimer's, whereas the alternate allele tracks with standard baseline risk. However, the evidence strength of rs3851050 as an independent clinical diagnostic tool remains limited. The effect size of any individual non-coding SNP at this locus confers an odds ratio that typically shifts risk by only 10% to 15%, demonstrating statistical association across massive populations rather than individual clinical certainty.
Ancestry and Population Distribution
According to the Genome Aggregation Database (gnomAD) and population genetics cohorts, rs3851050 is a common polymorphism found globally. The minor allele displays an estimated frequency of approximately 0.35 to 0.45 across individuals of European and East Asian ancestries, making heterozygous and homozygous carriers widespread. Because the allele frequencies are balanced across many major continental groups, carrying one or two copies of either allele is considered a normal, standard genomic finding. Despite this commonality, researchers caution that the magnitude of disease risk associations observed in genetic epidemiology studies has been predominantly calibrated in cohorts of European descent, highlighting the need for deeper functional and longitudinal validation across diverse ancestries.
Clinical Interpretation and Limitations
It is essential to distinguish between deterministic genetic mutations and common polygenic susceptibility variants. Unlike rare pathogenic mutations in genes such as APP, PSEN1, or PSEN2—which cause early-onset familial Alzheimer's disease—variants at the PICALM locus do not cause disease on their own. Possessing an allele associated with elevated risk does not mean an individual will develop dementia, nor does carrying a protective allele provide immunity. Late-onset Alzheimer's disease is complex and multifactorial, driven by thousands of subtle genetic loci acting in concert with lifestyle, cardiovascular health, age, and environmental factors. Genetic findings at rs3851050 should be viewed strictly as educational data rather than a medical prognosis, and clinical decisions should always be directed by qualified medical professionals.
How common is this variant?
The minor allele frequency for rs3851050 ranges between approximately 0.35 and 0.45 across European and Asian populations in gnomAD. Genotypes are widely distributed across global ancestries, making both homozygous and heterozygous states ordinary human variations.
Frequently asked questions
Does having the rs3851050 risk genotype mean I will get Alzheimer's disease?
No. The rs3851050 variant is a common susceptibility marker that alters relative statistical risk by only a small fraction. Many people who carry the risk-associated allele never develop dementia, while others without it do.
How does the PICALM gene affect the brain?
PICALM produces a protein essential for endocytosis, which is the process cells use to internalize molecules from their surroundings. In the brain, this mechanism helps regulate the clearance and degradation of amyloid-beta peptides and supports normal microglial and neuronal function.
Can a genetic test for rs3851050 be used for medical diagnosis?
No, clinical guidelines do not recommend testing individual non-APOE SNPs like rs3851050 for diagnostic purposes. Because its isolated effect size is very small, it cannot accurately predict an individual's cognitive future.
How does rs3851050 compare to the APOE gene?
APOE (specifically the epsilon 4 allele) is the strongest common genetic risk factor known for late-onset Alzheimer's disease, conferring several-fold increases in risk. By comparison, variants in PICALM such as rs3851050 have far smaller effects, shifting relative risk by only 10% to 15%.
Sources & further reading
Educational information only, last refreshed 9/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs3851050?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29